Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2021-12-20 Report Publication Anno…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Financial calendar
Report Publication Announcement Classification · 100% confidence The document text is titled 'Financial calendar' and lists scheduled dates for future corporate events, specifically mentioning 'Annual Report', 'Annual General Meeting', and 'Quarterly Report'. It is not the report itself, but rather a schedule of when reports/meetings will occur. Since it is an announcement about the timing and publication of future reports, it best fits the 'Report Publication Announcement' (RPA) category, which covers announcements regarding the timing or release of company reports. The document length is very short (593 chars), supporting the idea that it is an announcement rather than a full report.
2021-12-20 English
First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer
Legal Proceedings Report Classification · 99% confidence The document announces a specific corporate event: the enrollment of the first patient in a Phase II clinical trial (DOVACC) for the company's lead product (UV1). It includes details about the trial design, collaborators (NSGO-CTU, ENGOT, AstraZeneca), expected data timelines (2023), and quotes from management. This type of announcement, detailing progress in clinical development and operational milestones, is typically classified as a general regulatory announcement or news release, rather than a formal financial report (like 10-K or IR) or a specific financing/dividend event. Since it is a specific, material update that doesn't fit the other specialized categories (like DIRS, DIV, CAP, ER), the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for material, non-standard announcements.
2021-12-15 English
Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma
Regulatory Filings Classification · 95% confidence The document announces that Ultimovacs received Orphan Drug Designation (ODD) from the FDA for its UV1 cancer vaccine in metastatic melanoma. This is a specific, material event announcement concerning regulatory progress and clinical development, rather than a comprehensive financial report (like 10-K or IR) or a general shareholder communication (like DEF 14A or AGM-R). It is a specific regulatory/clinical update. Since there is no specific code for 'Regulatory/Clinical Update' that isn't already covered by a financial report or a specific legal notice, and given the nature of the announcement (a material event disclosure), it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements not covered by other specific codes like DIRS or LTR. The length (4701 chars) is substantial enough that it is the primary document, not just an announcement of a document (ruling 2 does not apply).
2021-12-02 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 99% confidence The document text is explicitly titled 'KRT-1500 Template for notification of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them'. This template is used to report insider trading or personal share transactions by directors and executives. This directly corresponds to the definition of Director's Dealing (DIRS). The content details the PDMR (Carlos Freitas De Sousa, CEO), the issuer (ULTIMOVACS ASA), the transaction type (Acquisition), price, volume, and date.
2021-12-02 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification of trade by primary insider' concerning the CEO, Carlos de Sousa, buying shares. This directly corresponds to the definition of Director's Dealing (insider trades) which is classified as DIRS.
2021-12-02 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing Classification · 100% confidence The document text explicitly uses the template title "KRT-1500 Template for notification of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them." It details a transaction (Acquisition of 1,000 shares) by a CEO (Carlos David Freitas de Sousa) of Ultimovacs ASA. This type of filing, reporting insider transactions by management, directly corresponds to the definition of Director's Dealing.
2021-11-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.